FLT3 and acute myeloid leukemia: The combination of a hypomethylating agent such as azacytidine or decitabine, with quizartinib or sorafenib, ameliorates the protection afforded by the bone marrow, inducing in vivo and ex vivo apoptosis, growth inhibition, and terminal differentiation in FLT3-ITD AML blasts [186].